We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Micap | LSE:MIC | London | Ordinary Share | GB0033274050 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.375 | - | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
28/4/2004 13:33 | except govt ain't got any money of its own - it's money they collect from you and me ;o) | m.t.glass | |
28/4/2004 13:29 | Department of Trade and Industry. Money from the Government. | stewartf | |
28/4/2004 12:10 | Can anyone tell me what "Dti funding" is please? chris | chrismonty | |
28/4/2004 12:07 | ok .. so I know it's a few weeks out of date but interesting to see what micap gets up to? Micap highlights research Apr 2 2004 Daily Post MERSEYSIDE bio-tech firm Micap yesterday held its first research day bringing together scientists, clients and investors. The Newton-le-Willows company, which specialises in the microencapsulation of active ingredients in yeast cells, hosted the event at Haydock Park Racecourse. Project managers from partners SkyePharma and flavour-fragrance house Firmenich attended, along with up to 40 scientists from Micap, its university partners and experts from the pharmaceutical, food and agricultural sectors. It looked specifically at how the company can further develop its technology for the benefit of the pharmaceutical, food and agricultural industries. The event came shortly after Micap announced its first licence agreement in pharmaceutical drug delivery, with SkyePharma worth more than £500,000. The exclusive licence will allow SkyePharma to use the technology in up to 10 pharmaceutical products. The company has recently secured more than £240,000 of research council and Dti funding. Good to see a bit of upward movement in the last few days too ! chris | chrismonty | |
28/4/2004 09:53 | This BB has gone quiet again with the fall in price.Just decided to take advantage of this low price and picked up 10k @59.5--let's be lucky. g | goldrush | |
07/4/2004 11:24 | 2pm next Thursday | grantb1 | |
07/4/2004 11:20 | When is the bounce coming | ricky9 | |
21/3/2004 13:51 | ...vernit so DO Micap have the technology that bprg needs, to incorporate flavours liked by dogs/cats etc? And could you see a useful link up here between the two companies? ( melly & mots could do with a Wafer Tab carrot flavoured for horses!) chris | chrismonty | |
17/3/2004 22:50 | Very disapointed in the company's lack of response - sent them a long e-mail a week ago about a number of technical issue and have heard zilch in reply. | mieke | |
17/3/2004 22:48 | vernit.... yes I realise that graham Hind said that about Micap ( thank you for your transcript of the whole thing!) But he also said that he was interested in vetinary uses for bprg's applications, and if bprg can incorporate a pill into their Wafer Tab product for eg getting a dog to swallow a pill, then the whole job would be so much easier if the taste /flavour of it was pleasant for the dog. This is where perhaps Micap have the technology for producing and incorporating a strong immediate flavour... of dog food or bone perhaps. I also seem to remember G.Hind joking? that when dealing with animals, medicines would be much easier to administer if they tasted ok to them. Still reckon it's a viable proposition. chris | chrismonty | |
16/3/2004 17:51 | chrismonty - at his interview on ADVFN, Graham Hind of Bioprogress (BPRG) had this to say of Micap: 'We meet a lot of companies we are always looking around, the networking thing. We have had a look at some of the products that Micap do as potential as to whether they could add value to what we are doing. Acquiring the company? I am not seriously in discussions about that'. | vernit | |
11/3/2004 12:38 | Well, there you go - predictably walloped today! May be due a bounce from here, but then again, who'd put their faith in that? Back to 66p as per pre-SKP announcement would be nice, though... :0) | taurusthebear | |
06/3/2004 15:03 | bioprogress results out on monday 8th march, so if there was any substance in the rumour of a deal with Micap, would perhaps expect it to be announced then,be interesting to see? >> banovallum..are you prepared and ready for the ride? ;~))) | chrismonty | |
05/3/2004 07:11 | SKP listed as a "Sell" in todays Investor chronicle. May have a short term impact here. G | grantb1 | |
04/3/2004 17:46 | Good healthy two way volume today - it looks as if for everyone keen to take a profit there is a buyer waiting to pick up the shares | tuffbet | |
04/3/2004 14:46 | Could be some good exposure here for MICAP SkyePharma to Present at SG Cowen's 24th Annual Health Care Conference in Boston LONDON and NEW YORK, March 4 /PRNewswire-FirstCal announces today that the Company's Chief Executive Officer, Michael Ashton, will make a presentation at SG Cowen's 24th Annual Health Care Conference at the Boston Marriott Copley Place Hotel in Boston, Massachusetts. Mr. Ashton will deliver his presentation on Thursday, March 11, 2004 at 8:00 a.m. (EST) and again at 9:00 a.m. (EST). Investors mayaccess a live webcast of the presentation at under the Investor Relations tab. About SkyePharma SkyePharma PLC develops pharmaceutical products benefiting from world-leading drug delivery technologies that provide easier-to-use and more effective drug formulations. There are now nine approved products incorporating three of SkyePharma's five technologies in the areas of oral, injectable, inhaled and topical delivery, supported by advanced solubilisation capabilities. Formore information, visit DATASOURCE: SkyePharma PLC CONTACT: Michael Ashton, Chief Executive Officer, +44-207-491-1777, or Peter Laing, Director of Corporate Communications, +44-207-491-5124, or Sandra Haughton, US Investor Relations, +1-212-753-5780, all of SkyePharma PLC; or Tim Anderson or Mark Court, both of Buchanan Communications, +44-207-466-5000, for SkyePharma PLC Web site: | tuffbet | |
04/3/2004 13:46 | Yes be a good Boy Gran and delete that offending post, and them you can get back to your favourite website.. | sheneeqa | |
04/3/2004 13:44 | PS. IVS is having a breakout if any of you are interested | grantb1 | |
04/3/2004 13:40 | hear hear! ;o) | m.t.glass | |
04/3/2004 13:39 | he was hardly ramping was he. just giving out the correct shareholdings as some on the board werent clear. thankyou again mr norris. | rambutan2 | |
04/3/2004 13:37 | jeez, what a response from a light hearted post !! I still couldnt care less about the CFO posting publically available information on this BB tho. But as long as he maximises my invesment, he can spend all day chatting on "dogging" websites with Stan Collymore for all I care. Yours, G | grantb1 | |
04/3/2004 13:27 | Simple pick up the phone if you seem that uncertain,seems an open sort of chappie. I am not. | sheneeqa |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions